225 related articles for article (PubMed ID: 20534285)
1. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis.
Loriga G; Ciccarese M; Pala PG; Satta RP; Fanelli V; Manca ML; Serra G; Dessole P; Cossu M
Transplant Proc; 2010 May; 42(4):1297-302. PubMed ID: 20534285
[TBL] [Abstract][Full Text] [Related]
2. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
4. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine versus everolimus: effects on the glomerulus.
Baas MC; Kers J; Florquin S; de Fijter JW; van der Heide JJ; van den Bergh Weerman MA; ten Berge IJ; Bemelman FJ
Clin Transplant; 2013; 27(4):535-40. PubMed ID: 23795805
[TBL] [Abstract][Full Text] [Related]
6. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
[TBL] [Abstract][Full Text] [Related]
7. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
Salvadori M; Scolari MP; Bertoni E; Citterio F; Rigotti P; Cossu M; Dal Canton A; Tisone G; Albertazzi A; Pisani F; Gubbiotti G; Piredda G; Busnach G; Sparacino V; Goepel V; Messa P; Berloco P; Montanaro D; Veroux P; Federico S; Bartezaghi M; Corbetta G; Ponticelli C
Transplantation; 2009 Nov; 88(10):1194-202. PubMed ID: 19935373
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
9. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial.
Paoletti E; Marsano L; Bellino D; Cassottana P; Cannella G
Transplantation; 2012 Mar; 93(5):503-8. PubMed ID: 22318246
[TBL] [Abstract][Full Text] [Related]
10. Plasma neutrophil gelatinase-associated lipocalin and worsening renal function during everolimus therapy after heart transplantation.
Imamura T; Kinugawa K; Doi K; Hatano M; Fujino T; Kinoshita O; Nawata K; Noiri E; Kyo S; Ono M
Int Heart J; 2015; 56(1):73-9. PubMed ID: 25742944
[TBL] [Abstract][Full Text] [Related]
11. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients.
Brunkhorst LC; Fichtner A; Höcker B; Burmeister G; Ahlenstiel-Grunow T; Krupka K; Bald M; Zapf A; Tönshoff B; Pape L
PLoS One; 2015; 10(9):e0135439. PubMed ID: 26407177
[TBL] [Abstract][Full Text] [Related]
14. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
Carvalho C; Coentrão L; Bustorff M; Patrício E; Sampaio S; Santos J; Oliveira G; Pestana M
Clin Transplant; 2011; 25(4):E401-5. PubMed ID: 21457330
[TBL] [Abstract][Full Text] [Related]
15. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
Lorber MI; Mulgaonkar S; Butt KM; Elkhammas E; Mendez R; Rajagopalan PR; Kahan B; Sollinger H; Li Y; Cretin N; Tedesco H;
Transplantation; 2005 Jul; 80(2):244-52. PubMed ID: 16041270
[TBL] [Abstract][Full Text] [Related]
16. Conversion from cyclosporine to sirolimus in stable renal transplant recipients.
Sennesael JJ; Bosmans JL; Bogers JP; Verbeelen D; Verpooten GA
Transplantation; 2005 Dec; 80(11):1578-85. PubMed ID: 16371929
[TBL] [Abstract][Full Text] [Related]
17. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
19. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate.
Wang SS; Chou NK; Chi NH; Huang SC; Wu IH; Wang CH; Yu HY; Chen YS; Tsao CI; Ko WJ; Shun CT
Transplant Proc; 2010 Apr; 42(3):938-9. PubMed ID: 20430209
[TBL] [Abstract][Full Text] [Related]
20. Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors.
Sánchez-Fructuoso AI; Ruiz JC; Calvo N; Rodrigo E; Perez-Flores I; Gómez-Alamillo C; Fernández-Pérez C; Arias M; Barrientos A
Transplantation; 2012 Feb; 93(4):398-405. PubMed ID: 22245871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
